Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells

Leukemia

Volumn 22, Issue 7, 2008, Pages 1354-1360

  MacPartlin, M ^a   Smith, A M ^b   Druker, B J ^a,c   Honigberg, L A ^b   Deininger, M W ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PHARMACYCLICS INC   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BRUTON TYROSINE KINASE; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL PROLIFERATION; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; HEMATOPOIETIC CELL; LEUKEMIA; LEUKEMOGENESIS; LYMPHOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MYELOID CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 47549101393     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.126     Document Type: Article

References (34)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
3. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
4. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57-60.
5. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA et al Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082-6093.
6. Miller AT, Berg LJ. New insights into the regulation and functions of Tec family tyrosine kinases in the immune system. Curr Opin Immunol 2002; 14: 331-340.
7. Yang WC, Collette Y, Nunes JA, Olive D. Tec kinases: A family with multiple roles in immunity. Immunity 2000; 12: 373-382.
8. Saouaf SJ, Mahajan S, Rowley RB, Kut SA, Fargnoli J, Burkhardt AL et al. Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc Natl Acad Sci USA 1994; 91 9524-9528.
9. Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM et al Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 1996; 271: 822-825.
10. Cheng G, Ye ZS, Baltimore D. Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction. Proc Natl Acad Sci USA 1994; 91: 8152-8155.
11. Middendorp S, Dingjan GM, Maas A, Dahlenborg K, Hendriks RW. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. J Immunol 2003; 171: 5988-5996.
12. Guo B, Kato RM, Garcia-Lloret M, Wahl MI, Rawlings DJ. Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex. Immunity 2000; 13: 243-253.
13. Feng S, Chen JK, Yu H, Simon JA, Schreiber SL. Two binding orientations for peptides to the Src SH3 domain: Development of a general model for SH3-ligand interactions. Science 1994; 266: 1241-1247.
14. Backesjo CM, Vargas L, Superti-Furga G, Smith CI. Phosphorylation of Bruton's tyrosine kinase by c-Abl. Biochem Biophys Res Commun 2002; 299: 510-515.
15. Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M et al. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med 2005; 201: 1837-1852.
16. Villuendas R, Steegmann JL, Pollan M, Tracey L, Granda A, Fernandez-Ruiz E et al. Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach. Leukemia 2006; 20 1047-1054.
17. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem 2007; 2: 58-61.
18. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149-7153.
19. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.
20. Honigberg LA, Smith AM, Chen J, Thiemann P, Verner E, Renschler M. Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo. Session Type: Poster Session, Board #746-1. Blood 2007 16 November 2007; 2007. p. 475A.
21. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829-3840.
22. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1: 479-492.
23. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987; 84: 6558-6562.
24. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
25. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 2003; 12: 27-37.
26. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937.
27. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
28. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
29. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C et al High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55-60.
30. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 2002; 359: 487-491.
31. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
32. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
33. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: A gene-expression study. Lancet 2002; 359: 481-486.
34. Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano- beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem 1999; 274: 9587-9599.